Mostrar el registro sencillo del ítem

Artículo

dc.creatorRecacha, E.es
dc.creatorMachuca, J.es
dc.creatorDíaz Alba, P.es
dc.creatorDocobo Pérez, Fernandoes
dc.creatorRodríguez Beltrán, Jerónimoes
dc.creatorRodríguez Martínez, José Manueles
dc.date.accessioned2017-10-23T16:28:18Z
dc.date.available2017-10-23T16:28:18Z
dc.date.issued2017
dc.identifier.citationRecacha, E., Machuca, J., Díaz Alba, P., Docobo Pérez, F.M., Rodríguez Beltrán, J. y Rodríguez Martínez, J.M. (2017). Quinolone Resistance Reversion by Targeting the SOS Response. mBio, 8 (5), 1-17.
dc.identifier.issn2150-7511es
dc.identifier.urihttp://hdl.handle.net/11441/65330
dc.description.abstractSuppression of the SOS response has been postulated as a therapeutic strategy for potentiating antimicrobial agents. We aimed to evaluate the impact of its suppression on reversing resistance using a model of isogenic strains of Escherichia coli representing multiple levels of quinolone resistance. E. coli mutants exhibiting a spectrum of SOS activity were constructed from isogenic strains carrying quinolone resistance mechanisms with susceptible and resistant phenotypes. Changes in susceptibility were evaluated by static (MICs) and dynamic (killing curves or flow cytometry) methodologies. A peritoneal sepsis murine model was used to evaluate in vivo impact. Suppression of the SOS response was capable of resensitizing mutant strains with genes encoding three or four different resistance mechanisms (up to 15-fold reductions in MICs). Killing curve assays showed a clear disadvantage for survival (Δlog10 CFU per milliliter [CFU/ml] of 8 log units after 24 h), and the in vivo efficacy of ciprofloxacin was significantly enhanced (Δlog10 CFU/g of 1.76 log units) in resistant strains with a suppressed SOS response. This effect was evident even after short periods (60 min) of exposure. Suppression of the SOS response reverses antimicrobial resistance across a range of E. coli phenotypes from reduced susceptibility to highly resistant, playing a significant role in increasing the in vivo efficacy.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherAmerican Society for Microbiologyes
dc.relation.ispartofmBio, 8 (5), 1-17.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectRecAes
dc.subjectSOS responsees
dc.subjectquinoloneses
dc.subjectresensitization of antibiotic-resistant bacteriaes
dc.subjectresistance reversiones
dc.titleQuinolone Resistance Reversion by Targeting the SOS Responsees
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Microbiologíaes
dc.relation.publisherversionhttp://dx.doi.org/ 10.1128/mBio.00971-17es
dc.identifier.doi10.1128/mBio.00971-17es
idus.format.extent18 p.es
dc.journaltitlemBioes
dc.publication.volumen8es
dc.publication.issue5es
dc.publication.initialPage1es
dc.publication.endPage17es

FicherosTamañoFormatoVerDescripción
pub 1mBio.00971-17.pdf575.9KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional